Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

Results from 5-year analysis of CheckMate 066 trial confirm benefit of nivolumab monotherapy as first-line treatment over dacarbazine (overall and progression free survival rates of 39% and 28%, respectively for nivolumab vs. 17 and 3%, respectively, with dacarbazine)

Journal of Clinical Oncology